Evidence map›Paper›PMID 37004570›Full record

ArticleEuropean radiology2023

A multicenter comparative matched-pair analysis of percutaneous tumor ablation and robotic-assisted partial nephrectomy of T1b renal cell carcinoma (AblatT1b study-UroCCR 80).

Grégoire Cazalas, Clément Klein, Gilles Piana, Eric De Kerviler, Afshin Gangi, Philippe Puech, Cosmina Nedelcu, Remi Grange, Xavier Buy, Marc-Antoine Jegonday and 11 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in European radiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 4 pooled it
5.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 4 syntheses or guidelines pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 12 institutions in 1 country.

Grégoire CazalasService d'imagerie diagnostique et thérapeutique de l'adulte, Hôpital Pellegrin, place Amélie-Raba-Léon, 33076, Bordeaux, France.
Clément KleinService d'urologie, andrologie et transplantation rénale, Hôpital Pellegrin, place Amélie-Raba-Léon, 33076, Bordeaux, France.
Gilles PianaDepartment of Radiology, Institut Paoli-Calmettes, Marseille, France.
Eric De KervilerDepartment of Radiology, Hôpital Saint-Louis 1, avenue Claude Vellefaux, 75010, Paris, France.
Afshin GangiDepartment of Interventional Radiology, University Hospital of Strasbourg, Strasbourg, France.
Philippe PuechDepartment of Radiology CHU Lille, Radiology Department, Lille, France.
Cosmina NedelcuDepartment of Radiology, University Hospital, CHU Angers, 4 rue Larrey, 49933, Angers, France.
Remi GrangeDepartment of Radiology, CHU Nord Saint-Etienne Avenue Albert Raimond, Saint Etienne, France.
Xavier BuyDepartment of Interventional Radiology, Institut Bergonié, Bordeaux, France.
Marc-Antoine JegondayDepartment of Radiology CHU Ponchaillou, Rennes, France.
Pierre BigotDepartment of Urology, University Hospital of Angers, Angers, France.
Charles Karim BensalahDepartment of Urology, CHU Ponchaillou, Rennes, France.
Victor GaillardDepartment of Urology, University Hospital of Strasbourg, Strasbourg, France.
Géraldine PignotDepartment of Urology, Institut Paoli-Calmettes, Marseille, France.
Philippe PaparelService d'Urologie, Centre Hospitalier Lyon Sud, Pierre Bénite, France.
Lionel BadetService d'Urologie, Hôpital Edouard Herriot, Lyon, France.
Clément MichielsService d'urologie, andrologie et transplantation rénale, Hôpital Pellegrin, place Amélie-Raba-Léon, 33076, Bordeaux, France.
Jean Christophe BernhardService d'urologie, andrologie et transplantation rénale, Hôpital Pellegrin, place Amélie-Raba-Léon, 33076, Bordeaux, France.
Olivier RouviereDepartment of Radiology - Pavillon B, Hôpital E. Herriot, 69003, Lyon, France.
Nicolas GrenierService d'imagerie diagnostique et thérapeutique de l'adulte, Hôpital Pellegrin, place Amélie-Raba-Léon, 33076, Bordeaux, France.
Clément MarcelinService d'imagerie diagnostique et thérapeutique de l'adulte, Hôpital Pellegrin, place Amélie-Raba-Léon, 33076, Bordeaux, France. clement.marcelin@gmail.com.ORCID http://orcid.org/0000-0002-2328-0952
Hôpital Pellegrin · FRHôpital Edouard Herriot · FRHôpital Pontchaillou · FRInstitut Paoli-Calmettes · FRUniversité de Strasbourg · FRCentre Hospitalier Universitaire d'Angers · FRCentre Hospitalier Universitaire de Lille · FRCentre Hospitalier Universitaire de Saint-Étienne · FRHôpital Lyon Sud · FRHôpital Saint-Louis · FRInstitut Bergonié · FRUniversité d'Angers · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveRenal cell carcinomas represent the sixth- and tenth-most frequently diagnosed cancer in men and women. Recently, percutaneous-guided thermal ablations have proved to be as effective as partial nephrectomy and safer for treating small renal masses (i.e.,  < 3 cm). This study compared the perioperative and recurrence outcomes of percutaneous thermal ablation (TA) and robotic-assisted partial nephrectomy (RAPN) for the treatment of T1b renal cell carcinomas (4.1-7 cm).

methodsRetrospective data from 11 centers on the national database, between 2010 and 2020, included 81 patients treated with thermal ablation (TA) and 308 patients treated with RAPN for T1b renal cell carcinoma, collected retrospectively and matched for tumor size, histology results, and the RENAL score. TA included cryoablation and microwave ablation. Endpoints compared the rate between the two groups: local recurrence, metastases, complications, renal function decrease, and length of hospitalization.

resultsAfter matching, 75 patients were included in each group; mean age was 76.6 (± 9) in the TA group and 61.1 (± 12) in the RAPN group, including 69.3% and 76% men respectively. The local recurrence (LR) rate was significantly higher in the TA group than in the PN group (14.6% vs 4%; p = 0.02). The LR rate was 20% (1/5) after microwave ablation, 11.1% (1/9) after radiofrequency ablation, and 14.7% (9/61) after cryoablation. The major complication rate (Clavien-Dindo  ≥ 3) was higher following PN than after TA (5.3% vs 0%; p < 0.001). Metastases, eGFR decrease, and length of hospitalization did not differ significantly between the two groups.

conclusionsThe local recurrence rate was significantly higher after thermal ablation; however, thermal ablation resulted in significantly lower rates of complications. Thermal ablation and robotic-assisted partial nephrectomy are effective treatments for T1b renal cancer; however, the local recurrence rate was higher after thermal ablation. KEY POINTS: • The local recurrence rate was significantly higher in the thermal ablation group than in the partial nephrectomy group. • The major complication rate (Clavien-Dindo ≥ 3) was higher following PN than after TA (5.3% vs. 0%; p < 0.001).

Indexed as

Carcinoma, Renal CellKidney NeoplasmsRobotic Surgical ProceduresAgedFemaleHumansMaleMatched-Pair AnalysisNephrectomyRetrospective StudiesTreatment OutcomeAblationKidney neoplasmNeoplasm recurrence, localRadiology, interventionalSurgery

Identifiers

PMID37004570
OpenAlexW4362506687

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.